PI3K (phosphoinositide 3-kinase) is a key regulator of cell growth, metabolism and survival. The frequent activation of the PI3K pathway in cancer has stimulated widespread interest in identifying potent and selective inhibitors of PI3K isoforms. The present paper highlights recent progress in identifying such molecules and the challenges that remain for efforts to pharmacologically target the PI3K family.

Keywords:
cancer, mammalian target of rapamycin (mTOR), p110, phosphatidylinositol, phosphoinositide 3-kinase (PI3K)
© 2007 The Biochemical Society
2007
You do not currently have access to this content.